Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Tysabri natalizumab regulatory update

Elan withdrew an application in the EU to expand the label of Tysabri natalizumab to include first-line treatment of relapsing-remitting multiple sclerosis (RRMS) that

Read the full 247 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE